全文获取类型
收费全文 | 12116篇 |
免费 | 639篇 |
国内免费 | 87篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 166篇 |
妇产科学 | 84篇 |
基础医学 | 1502篇 |
口腔科学 | 235篇 |
临床医学 | 737篇 |
内科学 | 2923篇 |
皮肤病学 | 243篇 |
神经病学 | 950篇 |
特种医学 | 828篇 |
外科学 | 2109篇 |
综合类 | 43篇 |
预防医学 | 398篇 |
眼科学 | 199篇 |
药学 | 764篇 |
中国医学 | 45篇 |
肿瘤学 | 1544篇 |
出版年
2023年 | 75篇 |
2022年 | 51篇 |
2021年 | 297篇 |
2020年 | 169篇 |
2019年 | 234篇 |
2018年 | 268篇 |
2017年 | 259篇 |
2016年 | 307篇 |
2015年 | 322篇 |
2014年 | 433篇 |
2013年 | 500篇 |
2012年 | 761篇 |
2011年 | 875篇 |
2010年 | 515篇 |
2009年 | 427篇 |
2008年 | 710篇 |
2007年 | 777篇 |
2006年 | 777篇 |
2005年 | 827篇 |
2004年 | 767篇 |
2003年 | 740篇 |
2002年 | 783篇 |
2001年 | 140篇 |
2000年 | 121篇 |
1999年 | 149篇 |
1998年 | 183篇 |
1997年 | 135篇 |
1996年 | 142篇 |
1995年 | 136篇 |
1994年 | 115篇 |
1993年 | 108篇 |
1992年 | 92篇 |
1991年 | 65篇 |
1990年 | 59篇 |
1989年 | 55篇 |
1988年 | 50篇 |
1987年 | 46篇 |
1986年 | 36篇 |
1985年 | 32篇 |
1984年 | 24篇 |
1983年 | 19篇 |
1982年 | 34篇 |
1981年 | 22篇 |
1980年 | 20篇 |
1979年 | 14篇 |
1977年 | 14篇 |
1974年 | 29篇 |
1973年 | 20篇 |
1972年 | 12篇 |
1969年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
1.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
2.
Kazuko Sakai Takayuki Takahama Mototsugu Shimokawa Koichi Azuma Masayuki Takeda Terufumi Kato Haruko Daga Isamu Okamoto Hiroaki Akamatsu Shunsuke Teraoka Akira Ono Tatsuo Ohira Toshihide Yokoyama Nobuyuki Yamamoto Kazuhiko Nakagawa Kazuto Nishio 《Molecular oncology》2021,15(1):126
The WJOG8815L phase II clinical study involves patients with non‐small cell lung cancer (NSCLC) that harbored the EGFR T790M mutation, which confers resistance to EGFR tyrosine kinase inhibitors (TKIs). The purpose of this study was to assess the predictive value of monitoring EGFR genomic alterations in circulating tumor DNA (ctDNA) from patients with NSCLC that undergo treatment with the third‐generation EGFR‐TKI osimertinib. Plasma samples of 52 patients harboring the EGFR T790M mutation were obtained pretreatment (Pre), on day 1 of treatment cycle 4 (C4) or cycle 9 (C9), and at diagnosis of disease progression or treatment discontinuation (PD/stop). CtDNA was screened for EGFR‐TKI‐sensitizing mutations, the EGFR T790M mutation, and other genomic alterations using the cobas EGFR Mutation Test v2 (cobas), droplet digital PCR (ddPCR), and targeted deep sequencing. Analysis of the sensitizing—and T790M—EGFR mutant fractions (MFs) was used to determine tumor mutational burden. Both MFs were found to decrease during treatment, whereas rebound of the sensitizing EGFR MF was observed at PD/stop, suggesting that osimertinib targeted both T790M mutation‐positive tumors and tumors with sensitizing EGFR mutations. Significant differences in the response rates and progression‐free survival were observed between the sensitizing EGFR MF‐high and sensitizing EGFR MF‐low groups (cutoff: median) at C4. In conclusion, ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib (Clinical Trial Registration No.: UMIN000022076).
Abbreviations
- CIs
- confidence intervals
- ctDNA
- circulating tumor DNA
- ddPCR
- droplet digital PCR
- EGFR
- epidermal growth factor receptor
- MFs
- mutant fractions
- NGS
- next‐generation sequencing
- NSCLC
- non‐small cell lung cancer
- ORR
- overall response rate
- OS
- overall survival
- PD
- progressive disease
- PFS
- progression‐free survival
- PR
- partial response
- SD
- stable disease
- TKI
- tyrosine kinase inhibitor
3.
4.
Tada Kazuhiro Iwashita Yukio Shiraiwa Ken Uchida Hiroki Oshima Yusuke Sato Yuhki Nakanuma Hiroaki Hirashita Teijiro Masuda Takashi Endo Yuichi Takeuchi Yu Ohta Masayuki Itoh Hiroki Inomata Masafumi 《Cancer chemotherapy and pharmacology》2020,85(2):345-352
Cancer Chemotherapy and Pharmacology - Chemotherapy after hepatectomy for colorectal liver metastasis has not been established, due to the toxic side effects, which are likely related to impaired... 相似文献
5.
6.
Hibiki Udagawa Keisuke Kirita Tomoyuki Naito Shogo Nomura Masayuki Ishibashi Reiko Matsuzawa Kakeru Hisakane Yuko Usui Shingo Matsumoto Kiyotaka Yoh Seiji Niho Genichiro Ishii Koichi Goto 《Cancer science》2020,111(7):2488-2498
Cryoprobe is a novel transbronchial biopsy (TBB) tool that yields larger tissue samples than forceps. Pathological diagnosis and biomarker analysis, such as genetic alterations and programmed death‐ligand 1 (PD‐L1) expression, are paramount for precision medicine against lung cancer. We evaluated the safety and usefulness of cryoprobe TBB for lung cancer diagnosis and biomarker analysis. In this single‐center, prospective single‐arm study, patients suspected of having or diagnosed with primary lung cancer underwent cryoprobe TBB using flexible bronchoscopy after conventional forceps TBB from the same lesion. Cryoprobe TBB was performed in 121 patients. The incidence rate of severe bleeding and serious adverse events (4% [90% confidence interval: 2%‐9%]) was significantly lower than the expected rate (20% with 30% threshold, P < 0.01). Combining both central and peripheral lesions, the diagnostic yield rate of cryoprobe samples was 76% and that of forceps samples was 84%. Compared with forceps TBB samples, cryoprobe TBB samples were larger (cryoprobe 15 mm2 vs forceps 2 mm2) and resulted in a larger proportion of definite histomorphological diagnosis (cryoprobe 86% vs forceps 74%, P < 0.01), larger amounts of DNA extracted from samples (median: cryoprobe, 1.60 µg vs forceps, 0.58 µg, P = 0.02) and RNA (median: cryoprobe, 0.62 µg vs forceps, 0.17 µg, P < 0.01) extracted from samples, and tended to yield greater rates of PD‐L1 expression >1% (51% vs 42%). In conclusion, cryoprobe is a safe and useful tool for obtaining lung cancer tissue samples of adequate size and quality, which allow morphological diagnosis and biomarker analysis for precision medicine against lung cancer. 相似文献
7.
Taisuke Inada Satoshi Fukushima Masayuki Murai Masatoshi Jinnin Azusa Miyashita Satoshi Nakahara Junji Yamashita Jun Aoi Shinichi Masuguchi Hironobu Ihn 《The Journal of dermatology》2015,42(2):198-201
miRNA‐221 (miR‐221) is known to be abnormally expressed in many human cancers. The serum levels of miR‐221 have been reported as a tumor marker for malignant melanoma (MM). We hypothesized that the hair shaft miR‐221 levels may be increased in patients with MM. We therefore assessed the possibility that hair shaft miR‐221 levels could be a marker for MM. The hair shaft miR‐221 levels were significantly higher in patients with MM than controls. The rates of increased hair shaft miR‐221 levels above the cut‐off value were comparable to those of serum 5‐S‐CD, which is a tumor marker commonly used for MM. Measurements of the hair shaft miR‐221 levels could have potential clinical value in the detection of MM. This is the first report investigating the hair shaft levels of an miRNA in patients with MM. Our investigations offer new insight into the relationship between miR‐221 and MM, and may provide a new, non‐invasive way to screen for melanoma. 相似文献
8.
9.
Sustained virologic response achieved after curative treatment of hepatitis C virus‐related hepatocellular carcinoma as an independent prognostic factor 下载免费PDF全文
Naoya Kanogawa Sadahisa Ogasawara Tetsuhiro Chiba Tomoko Saito Tenyu Motoyama Eiichiro Suzuki Yoshihiko Ooka Akinobu Tawada Tatsuo Kanda Shigeru Mikami Ryosaku Azemoto Takashi Kaiho Masami Shinozaki Masayuki Ohtsuka Masaru Miyazaki Osamu Yokosuka 《Journal of gastroenterology and hepatology》2015,30(7):1197-1204